Skip to main content

Table 2 Basic hemodynamic data of the study groups

From: The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus

Variable Co CoCin DiabCo DiabCin Pdiabetes Ptreatment Pinteraction
HR (beats/min) 231 ± 11 246 ± 12 208 ± 8* 204 ± 10* 0.003 0.608 0.351
MAP (mmHg) 80.0 ± 2.0 81.0 ± 3.5 63.7 ± 2.5* 64.4 ± 3.1* <0.001 0.845 0.969
LVSP (mmHg) 99.5 ± 2.6 103.5 ± 2.1 85.5 ± 1.3* 82.3 ± 2.3* <0.001 0.858 0.102
SW (mmHg µl) 14,561 ± 1060 13,293 ± 948 9789 ± 592* 12,032 ± 1067 0.003 0.611 0.072
CO (µl/min) 42,347 ± 2472 41,306 ± 2804 33,360 ± 2162 38,605 ± 4288 0.057 0.484 0.297
EF (%) 70.42 ± 2.50 68.17 ± 2.70 58.09 ± 2.54* 68.02 ± 2.56 0.021 0.146 0.024
dP/dtmax (mmHg/s) 6539 ± 240 6804 ± 188 4933 ± 207* 4785 ± 230* <0.001 0.791 0.350
dP/dtmin (mmHg/s) −6135 ± 362 −6570 ± 446 −3883 ± 133* −3723 ± 248* <0.001 0.679 0.374
LVEDP (mmHg) 7.0 ± 0.6 7.2 ± 0.4 9.7 ± 0.7* 6.8 ± 0.3† 0.026 0.082 0.034
Tau (Weiss; ms) 10.3 ± 0.3 10.1 ± 0.3 17.3 ± 0.8* 14.9 ± 0.6*† <0.001 0.016 0.054
  1. Heart rate (HR), mean arterial pressure (MAP), maximal left ventricular (LV) systolic pressure (LVSP), stroke work (SW), cardiac output (CO), ejection fraction (EF), maximal slope of systolic pressure increment (dP/dtmax) and diastolic pressure decrement (dP/dtmin), LV end-diastolic pressure (LVEDP) and time constant of LV pressure decay (Tau) are shown. Groups: vehicle-treated controls (Co), cinaciguat-treated controls (CoCin), vehicle-treated diabetic (DiabCo) and cinaciguat-treated diabetic (DiabCin) animals. Values are mean ± SEM of 9–11 experiments per group
  2. * P < 0.05 vs. Co
  3. P < 0.05 vs. DiabCo (Tukey HSD test)